Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBDIND […]
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of […]
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AMLPhase 1a/b study in B-cell malignancies continues […]
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and […]